Due to interest from our existing client base we have opened our Biotech fund before its planned IPO in Q4 2019.
We bring more than 20 years of analyzing and trading biotech companies. We put all that experience into a very promising model that focuses on latestage biotech companies with Breakthrough Designation from the FDA.
If you are interested and able to invest more than €100,000 then please contact us and we will onboard you in the new fund.
Please contact either:
Peter Hildebrandt : email@example.com
Lars Fetterlein : firstname.lastname@example.org
Stefan Rasmussen : email@example.com
or by phone + 45 3930 6080